CNS biomarkers from blood
Brain-derived biomarkers from a routine blood draw
NeuroDex’s ExoSORT™ platform isolates extracellular vesicles released into blood by brain cells, such as neurons and oligodendrocytes, to measure target engagement, pharmacodynamics and disease biology. Every assay runs in our GCLP-aligned laboratories in Natick, MA, from preclinical studies through clinical trials.

Why brain-derived
Why measure biomarkers inside brain-derived vesicles?
Blood markers like NfL tell you the brain is injured, not whether your drug reached its target. Proteins such as α-synuclein and TDP-43 are made throughout the body, so a plain plasma reading mixes brain and non-brain signal. ExoSORT™ enriches the vesicles that brain cells, such as neurons and oligodendrocytes, release into blood, so the readout reflects brain biology.
Phase 2b
Trial-proven
Neuron-derived TDP-43 measured in our lab was a registered primary outcome in the PARADIGM ALS trial (NCT05357950).
>80%
Checked against CSF
Sensitivity and specificity of neuron-derived α-synuclein for predicting CSF seeding-assay positivity (N=150 PD and LBD).
500 µL
Built for trials
EDTA plasma per sample, with reports typically 2–3 weeks after receipt.
40+
Backed by the field
Pharma and biotech collaborations, with funding from the Michael J. Fox Foundation, ADDF and Target ALS.
Brain-derived biomarker panels for CNS drug development
Evidence
Funded, peer-reviewed and used in clinical trials
1,062+
Open dataset
Neuron-derived EV RNA-seq samples from about 356 PDBP participants, released in AMP PD Release 4.3.
About the dataset1,304
Autopsy-validated
With Columbia University: α-synuclein in neuron-derived vesicles was elevated in Lewy body pathology confirmed at autopsy.
Read the studyGLP-1
CNS target engagement
With Stanford: first evidence of CNS target engagement for GLP-1 and PPARγ agonists from blood (JCEM, 2026).
Read the study17
Peer-reviewed papers
Publications on brain-derived extracellular vesicles, from 2016 to 2026.
See publicationsBiomarker services for CNS drug development
NeuroDex works with pharma and biotech teams from target validation through clinical trials. Our brain-derived extracellular vesicle panels give your program target-engagement, pharmacodynamic and stratification readouts from plasma, with no lumbar puncture, run in our GCLP-aligned laboratory.
Target engagement
Pharmacodynamics
GCLP-aligned quality
Patient stratification
Parkinson's disease and synucleinopathy
α-synuclein for stratification and target engagement in synucleinopathy programs.
ALS
TDP-43 for ALS and FTD programs, including a Phase 2b primary outcome.
Alzheimer's disease
Tau/pTau and synaptic markers for Alzheimer’s drug programs.
Neuroinflammation
NF-κB pathway activity for anti-inflammatory CNS programs.
Autophagy, Brain injury
LC3 and cathepsin D for autophagy–lysosome programs.
Before you commit samples
Request a sample-feasibility review
Tell us your target, sample type and volume, number of visits and study size. We will tell you which panels fit, what your banked samples can support and the expected turnaround, typically 2–3 weeks from sample receipt.




